SecBot SecBot
SECBOTREPLAY Home › Report › LFCR

LFCR · Lifecore Biomedical (LFCR) has entered into a new development services…

Lifecore Biomedical, Inc. · PRESS-RELEASE filed Mar 4, 2026 at 16:03 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 4, 2026 at 16:03 ET

Lifecore Biomedical (LFCR) has entered into a new development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid drug candidate for at-home treatment of inflammatory acne using Indomo's ClearPen™ self-injection device. This expands their existing collaboration and supports Indomo's planned Phase 2 clinical trials in 2026, highlighting Lifecore's growing role in autoinjector-based therapeutics beyond its traditional ophthalmic focus.

  • Lifecore will produce engineering and clinical batches of DT-001 for Indomo’s acne treatment program.
  • This is the second agreement between Lifecore and Indomo, expanding prior formulation and process optimization work.
  • The drug candidate DT-001 is designed for use with Indomo’s investigational ClearPen™ intradermal self-injection device.
  • Indomo aims to advance into Phase 2 clinical trials in 2026; the product is not yet FDA-approved.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access